Quick Answer
Tvardi Therapeutics, Inc. reported Net Income of -$18.21 million for fiscal year 2025.
Tvardi Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$18.21M | +38.0% |
| 2024 | -$29.40M | +75.2% |
| 2023 | -$118.51M | -38.7% |
| 2022 | -$85.47M | +3.4% |
| 2021 | -$88.44M | -1151.6% |
| 2020 | $8.41M | +107.9% |
| 2019 | -$106.37M | -43.7% |
| 2018 | -$74.01M | -27.3% |
| 2017 | -$58.12M | -1.5% |
| 2016 | -$57.28M | -132.0% |
| 2015 | -$24.69M | -39.1% |
| 2014 | -$17.75M | -347.8% |
| 2013 | -$3.96M | +36.8% |
| 2012 | -$6.27M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.53M | -0.3% | -232.6% |
| June 30, 2025 | $4.17M | +159.7% | +143.5% |
| March 31, 2025 | -$9.58M | -128.0% | -73.8% |
| September 30, 2024 | -$5.51M | +80.3% | +21.0% |
| June 30, 2024 | -$6.97M | +77.8% | -66.0% |
| March 31, 2024 | -$4.20M | +84.2% | +85.0% |
| September 30, 2023 | -$28.03M | -20.9% | +11.0% |
| June 30, 2023 | -$31.48M | -648.4% | -18.1% |
- Tvardi Therapeutics, Inc. showed an increase of +38.0% in Net Income compared to the prior fiscal year.
- Over the 2012–2025 period, Tvardi Therapeutics, Inc.’s net income has declined by 190.4% (from -$6.27 million to -$18.21 million).
- The most recent figure is from Tvardi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: